Pruritus - Pipeline Insight, 2024

This “Pruritus - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pruritus: Understanding

Pruritus: Overview

Pruritus, or itching, is a frequent complaint heard by dermatologists and primary care physicians. Although generally considered a benign symptom, pruritus can have adverse effects on a patient’s wellbeing and can be incapacitating when severe. The mechanisms of pruritus are not particularly well understood and are compounded by the subjective nature of the process itself. Pruritus occurs with a host of dermatological conditions, but can also be a marker of systemic disease. Dermatologists and primary care physicians must be aware of the varied causes of itching. Pruritus can range from mild irritation to intense discomfort and can affect localized areas or the entire body. Managing pruritus often involves identifying potential triggers and adopting preventive measures to alleviate symptoms and improve comfort.

When evaluating the patient with significant pruritus, the physician should obtain a careful history, paying attention to the severity and quality of the itching and the influence of environmental factors. The physician should try to assess the patient’s overall psychological state and the degree of disruption of his or her lifestyle. During physical examinations, careful note should be made of primary skin lesions, which may suggest a dermatological diagnosis, as well as secondary lesions from scratching.

Itch has been categorized into the following four classifications: cutaneous, neuropathic, neurogenic, and psychogenic. Cutaneous itch, also referred to as pruritoceptive itch, is due to inflammation of the skin. Neuropathic itch is caused by an itch that arises anywhere along the afferent nerve pathway due to damage of the nervous system. It is typically seen in herpetic neuralgia, multiple sclerosis, and brain tumors. Neurogenic itch originates centrally without evidence of neuronal pathology, as seen in cholestasis. Lastly, psychogenic itch is seen in delusional states, such as parasitophobia.

"Pruritus- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritus pipeline landscape is provided which includes the disease overview and Pruritus treatment guidelines. The assessment part of the report embraces, in depth Pruritus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Pruritus.

Pruritus Emerging Drugs Chapters

This segment of the Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pruritus Emerging Drugs

Tradipitant: Vanda Pharmaceuticals

Tradipitant is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. Currently, the drug is in Phase III stage of its clinical trial evaluation for the treatment of Pruritus.

Vixarelimab: Roche

Vixarelimab is an investigational fully-human monoclonal antibody that targets OSMRβ, which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes vixarelimab to be the only monoclonal antibody in development that targets both pathways simultaneously. Kiniksa’s lead indication for vixarelimab is prurigo nodularis, a chronic inflammatory skin condition characterized by severely pruritic skin nodules. Currently, the drug is in the Phase II stage its clinical trial evaluation for the treatment of Pruritus.

KM-001: Kamari Pharma Ltd.

KM-001 is a TRPV3 antagonist administered orally and topically to target itch associated various skin conditions like Pachyonychia Congenita, Lichen Simplex Chronicus, and other related disorders. Currently, the drug is in the Phase I stage its clinical trial evaluation for the treatment of Pruritus.

Pruritus: Therapeutic Assessment

This segment of the report provides insights about the different Pruritus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pruritus

• There are approx. 20+ key companies which are developing the therapies for Pruritus. The companies which have their Pruritus drug candidates in the most advanced stage, i.e. Phase III include, Vanda Pharmaceuticals.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pruritus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pruritus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritus drugs.

Pruritus Report Insights

• Pruritus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pruritus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pruritus drugs?
• How many Pruritus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pruritus?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pruritus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pruritus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vanda Pharmaceuticals
• Roche
• Kamari Pharma Ltd.
• AB Science
• Haisco Pharmaceuticals
• Mirum Pharmaceuticals
• Incyte Corporation
• GlaxoSmithKline
• Shenyang Sunshine Pharmaceutical Co.
• Asana BioSciences
• Galderma R&D

Key Products

• Tradipitant
• Vixarelimab
• KM-001
• Masitinib
• HSK21542
• Volixibat
• Povorcitinib
• GSK2330672
• Nalfurafine Hydrochloride
• ASN008 TG
• Nemolizumab

This product will be delivered within 1-3 business days.